Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 42, 2022 - Issue 5
Submit an article Journal homepage
94
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Effects of spironolactone on dysmenorrhoea: a case report

Mariko Nakaharaa Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5187-2624
ORCID Icon,
Mika Tanakab Ebisu Mika Ladies Clinic, Tokyo, Japan
,
Kanako Murataa Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
,
Yuko Matsudaa Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
,
Yasuka Miyakunia Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
,
Fuyuko Nagaia Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
&
Kentaro Miyaia Department of Gynaecology, Tobu Chiiki Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan
 show all
Pages 1602-1604 | Published online: 12 Feb 2022

References

  • Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. 2019. Patiromer versus placebo enables spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet 394:1540–1550.
  • Badawy AM, Elnashar AM, Mosbah AA. 2012. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica 91:489–495.
  • Burnet RB, Radden HS, Easterbrook EG, McKinnon RA. 1991. Premenstrual syndrome and spironolactone. The Australian & New Zealand Journal of Obstetrics and Gynaecology 31:366–368.
  • Cachofeiro V, Miana M, de las Heras N, Martín-Fernández B, Ballesteros S, Fernández-Tresguerres J, et al. 2008. Aldosterone and the vascular system. The Journal of Steroid Biochemistry and Molecular Biology 109:331–335.
  • Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. 2017. Spironolactone. Journal of Pain and Symptom Management 53:288–292.
  • Cranston WI, Juel-Jensen BE. 1962. The effects of spironolactone and chlorthalidone on arterial pressure. The Lancet 279:1161–1164.
  • Genazzani AR, Mannella P, Simoncini T. 2007. Drospirenone and its antialdosterone properties. Climacteric 10:11–18.
  • Khan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, et al. 2010. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Human Reproduction 25:2878–2890.
  • Makabe T, Koga K, Miyashita M, Takeuchi A, Sue F, Taguchi A, et al. 2017. Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells. Journal of Reproductive Immunology 119:44–48.
  • Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri C, et al. 1999. Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. Journal of Clinical Endocrinology and Metabolism 84:1250–1254.
  • Osuga Y, Watanabe M, Hagino A. 2017. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. The Journal of Obstetrics and Gynaecology Research 43:1441–1448.
  • Schane HP, Potts GO. 1978. Oral progestational activity of spironolactone. The Journal of Clinical Endocrinology and Metabolism 47:691–694.
  • Schindler AE. 2008. Non-contraceptive use of hormonal contraceptives. Gynecological Endocrinology 24:235–236.
  • Seo JW, Lee DY, Yoon BK, Choi D. 2017. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. European Journal of Obstetrics, Gynecology, and Reproductive Biology 212:9–12.
  • Vizzardi E, Pina PD, Caretta G, Bonadei I, Sciatti E, Lombardi C, et al. 2015. The effect of aldosterone-antagonist therapy on aortic elastic properties in patients with nonischemic dilated cardiomyopathy. Journal of Cardiovascular Medicine 16:597–602.
  • Wang M, Hammarbäck S, Lindhe BÅ, Bäckström T. 1995. Treatment of premenstrual syndrome by spironolactone: a double‐blind, placebo‐controlled study. Acta Obstetricia et Gynecologica Scandinavica 74:803–808.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.